Preventive effect of zoledronic acid on bone loss around the prosthesis stem after hip replacement

doi:10.3969/j.issn.2095-4344.2015.35.004

Abstract

Abstract:

BACKGROUND: Bone loss to different degrees may appear within 1 year after hip replacement in the femoral or acetabular sides, and severely affect long-term stability of the prosthesis and bone strength. Thus, to reduce bone loss around the prosthesis stem after total hip replacement is significant to prolong the use time of the prosthesis and to prevent fractures surrounding the prosthesis.
OBJECTIVE: To observe the preventive effect of zoledronic acid on bone loss surrounding the prosthesis stem after hip replacement.
METHODS: A total of 80 patients after total hip replacement in the People’s Hospital of Shenxian from February 2011 to September 2014 were enrolled in this study. They were divided into two groups (n=40). At 4 days after replacement, patients in the observation group received treatment with zoledronic acid, but those in the control
group did not give zoledronic acid. The rest medication was identical between the two groups. Bone mineral density in the hip was measured before replacement and at 1 year after replacement in both groups. Serum calcium and phosphorus levels and alkaline phosphatase activities were observed before replacement, 3 days and 1 year after medication in the two groups. Adverse reaction during medication was recorded in the observation group.
RESULTS AND CONCLUSION: The average bone mineral density was significantly decreased in both groups at 1 year after replacement, and significant differences were found as compared with before replacement (P < 0.05). The average bone mineral density was significantly higher in the observation group than in the control group at 1 year after replacement (P < 0.05). Calcium and phosphorus levels were significantly diminished at 3 days after medication as compared with that before replacement (P < 0.05). Calcium and phosphorus levels maintained at the level before replacement at 1 year after medication. Alkaline phosphatase activities were slightly reduced within a short time after replacement in both groups, but no significant difference was found as compared with before replacement (P > 0.05). Alkaline phosphatase activities were low in the observation group at 1 year after medication, and significant difference was detected as compared with the control group and that before replacement (P < 0.05). No significant difference in alkaline phosphatase activities was detectable in the control group between 1-year post medication and pre-replacement (P > 0.05). Within two or three days after medication, nine patients suffered from varying degrees of muscle aches and fever in the observation group, and above symptoms were lessened after taking acetaminophen. These results verify that after total hip replacement, zoledronic acid injection can effectively prevent bone loss around the prosthesis in early stage after replacement, but fever symptoms may occur within a week after replacement. Thus, it is recommended that zoledronic acid injection can be given at 1 week after replacement. If fever and other symptoms appear, acetaminophen can be given.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

Key words: Arthroplasty, Replacement, Hip, Bone Density, Alkaline Phosphatase

CLC Number:

R318

Liu Guo-qing, Yuan Zhen-feng, Liu Peng, Pang Tong-tao, Zhang Xian-wei. Preventive effect of zoledronic acid on bone loss around the prosthesis stem after hip replacement [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(35): 5593-5597.

Figures/Tables 4

References

[1] Klingenstein GG, Yeager AM, Lipman JD, et al. Computerized range of motion analysis following dual mobility total hip arthroplasty, traditional total hip arthroplasty, and hip resurfacing. J Arthroplasty. 2013;28(7):1173-1176.
[2] 叶川,刘日光,汤晋,等.膝骨性关节炎双侧同期全膝关节置换和单侧膝关节置换的比较[J].中国组织工程研究,2014,18(35): 5583-5588.
[3] 曲新华,郝永强.双膦酸盐在骨科相关疾病治疗中的地位及再认识[J].中华骨科杂志,2014,34(1):78-80.
[4] Schiffern AN, Stevenson DA, Carroll KL, et al. Total hip arthroplasty, hip osteoarthritis, total knee arthroplasty, and knee osteoarthritis in patients with developmental dysplasia of the hip and their family members: A kinship analysis report. J Pediatr Orthop. 2012;32(6):609-612.
[5] 刘洁珍,黄雪萍,陈翠萍,等.功能康复训练路径对全髋关节置换术后假体周围骨量的影响[J].国际护理学杂志,2012,31(3): 481-483.
[6] 曾建春,曾意荣,樊粤光,等.唑来膦酸预防全髋关节置换术后早期骨丢失的初步临床研究[J].中国骨质疏松杂志,2014,20(7): 795-799.
[7] 倪小青,卢全中,潘风雨,等.唑来膦酸预防高龄骨质疏松骨折全髋关节置换术后骨丢失的临床研究[J].临床和实验医学杂志,2015, 14(5):391-393.
[8] 张丽娜,杨艳芳,顾林,等.唑来膦酸在早期乳腺癌中的抗肿瘤研究进展[J].中国肿瘤临床,2013,40(16):1005-1007.
[9] 许洁,丁玉.唑来膦酸治疗糖皮质激素所致骨质疏松症的护理[J].江苏医药,2012,38(16):1979-1980.
[10] 王利,哈巴西•卡肯,殷剑,等.唑来膦酸钠治疗全髋关节置换术后早期假体周围骨密度变化[J].中华临床医师杂志(电子版),2014, 8(15):2898-2900.
[11] 曾建春,曾意荣,樊粤光,等.唑来膦酸预防全髋关节置换术后早期骨丢失的初步临床研究[J].中国骨质疏松杂志,2014,20(7): 795-799.
[12] 杜哲,李明,张元凯,等.密固达静滴辅助人工股骨头置换术治疗骨质疏松性股骨颈及粗隆间骨折[J].山东医药,2013,53(15):83-84.
[13] 臧学慧,孙辉,高立华,等.全膝关节置换后假体周围应力与骨密度的相关性[J].中国组织工程研究,2014,18(44):7071-7076.
[14] 乔志,王义生,殷力,等.全髋及全膝关节置换后下肢深静脉血栓形成的季节因素[J].中国组织工程研究,2014,18(13):2000-2005.
[15] 陈楚娴,彭松林,赵坚,等.对乙酰氨基酚预防唑来膦酸不良反应用药时机的探讨[J].全科护理,2014,12(16):1441-1442.